摘要
目的:探讨SALL4/BMI-1基因在多发性骨髓瘤患者中基因表达及其临床意义。方法:应用实时荧光定量PCR技术,对54例多发性骨髓瘤,6例巨球蛋白血症进行SALL4/BMI-1基因的定量检测,并选择10例健康志愿者作为对照组。结果:SALL4/BMI-1基因在健康对照骨髓中不表达,在巨球蛋白患者中低表达,而骨髓瘤患者明显增高有显著差异性(P<0.05)。在骨髓瘤各亚型中,轻链型表达明显高于其他亚型(P<0.05),而且SALL4/BMI-1基因的表达与骨髓瘤的分呈正相关(P<0.05)。BMI-1与SALL4的表达规律一致,两者表达水平有显著相关性(P<0.01)。结论:SALL4/BMI-1基因在骨髓瘤患者高表达,而且与骨髓瘤的临床分期和轻链型有密切关系,可能作为临床判断预后和检测微小残留的一个指标。
Objective：To investigate the expression of SALL4 and BMI-1 mRNA in multiple myeloma（MM） and it′s clinical significances.Methods： We have measured the SALL4 and BMI-1 mRNA expression in 54 myeloma patients and 6 waldenstorm′s macroglobulinemia,10 healthy donors as controls group by real-time quantitative polymerase chain reaction（RQ-PCR）.Results： The expression of SALL4 and BMI-1 mRNA in myeloma patients was higher than that of in waldenstorm＇s macroglobulinemia and healthy groups,The difference between Light-chain of MM and other subtypes were statistically significant（P0.05）.There have positive relation between SALL4 and BMI-1 and grade of MM（P0.05）.The expression of BMI-1 was positively correlated with that of SALL4 in leukemia（r=0.825,P0.01）.Conclusion： High expression of SALL4 and BMI-1 mRNA in myeloma make sense for monitoring minimal residual disease and prognosis.
出处
《中国卫生检验杂志》
CAS
2011年第2期290-292,共3页
Chinese Journal of Health Laboratory Technology
